No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Yantai Zhenghai Biotechnology Co., Ltd., founded in 2003 and based in Yantai, China, specializes in the innovation, manufacturing, and commercialization of regenerative medical materials across China. The company's product offerings include a bone repair material, which is a partially deproteinized substance derived from calf cancellous bone after undergoing a series of processes like decellularization and degreasing. It also provides membranes for oral cavity repair, specifically designed to address shallow soft tissue defects in the mouth. Under the "Heal-All" brand, it supplies biomembranes used in neurosurgical procedures to mend defects of the cerebral dura mater. Additionally, the "Heal-Full" brand encompasses skin repair membranes developed for treating wounds within the dermal layer.
www.zhbio.comNo one on the platform currently holds 300653.SZ.
No tracked institution reports a position in 300653.SZ as of their last filing.
No one on the platform has traded 300653.SZ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 10.1% | — | — | — | ||
| Rev. Growth % | 0.3% | 4.4% | ||||
| Profit Margin % | 22.6% | 38.2% | 37.3% | |||
| Free Cash Flow Margin % | 24.2% | |||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $329M | -6.2% | $0.36 | $0.34–$0.39 | — | 2 |
| 2027 | $339M | +3.0% | $0.39 | $0.36–$0.41 | — | 2 |
| 2028 | $343M | +1.0% | $0.44 | $0.44–$0.44 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| $10.88 |
| +0.83% |
| $2.9B |
| — |
| 300878.SZZhejiang Wecome Pharmaceutical Company Limited | $31.89 | +1.24% | $4.5B | — |
| 603739.SSQingdao Vland Biotech Inc. | $12.13 | -0.90% | $3.1B | — |
Source: Financial Modeling Prep · peers by sector/industry